Prof. Xiugui Sheng 盛修贵
Chief Physician, Professor
Gynecology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Deputy Head, Radiation Oncology (gynecologic cancers)
Checked against a public report (2026-11). Positions change; the hospital's website is the final word.
Clinical focus: Comprehensive prevention and treatment of gynecologic tumors, including radical surgery for cervical, ovarian, and endometrial cancers. Expertise in chemotherapy, targeted therapy, and radiotherapy for these conditions.
Dr. Sheng holds a doctorate in oncology and has 29 years of experience in gynecologic tumor prevention and treatment. A Taishan Scholar and doctoral supervisor, Dr. Sheng leads research on conformal intensity-modulated radiotherapy, sentinel lymph node biopsy, and fertility-sparing surgeries. Dr. Sheng has led multiple national and provincial research projects and published over 260 papers.
Professional roles
- Former Chair, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Leader, Chinese Brachytherapy Collaboration Group
- Vice Chair, Obstetrics and Gynecology Professional Committee, Shandong Medical Association
- Deputy Editor-in-Chief, Chinese Journal of Cancer Prevention and Treatment
Name order: in Chinese the family name comes first (Sheng Xiugui). Papers usually list the name as Xiugui Sheng or Sheng X.
Selected publications
20 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Curr Oncol, 2026 (senior author): Lattice Radiation Therapy Plays a Synergistic Role in the Radical Treatment of Bulky Cervical Cancer: A Case Report and Literature Review. PubMed 42041715
- J Immunother, 2025 (senior author): Clinical Efficacy and Safety of Cadonilimab Immunotherapy in Advanced Cervical Cancer: A Retrospective Study. PubMed 40836400
- J Cell Mol Med, 2024 (senior author): HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway. PubMed 39431349
- Mol Biol Rep, 2023 (senior author): Role of GPX4 inhibition-mediated ferroptosis in the chemoresistance of ovarian cancer to Taxol in vitro. PubMed 37924448
- Cancer Sci, 2022 (senior author): The HOXC-AS2/miR-876-5p/HKDC1 axis regulates endometrial cancer progression in a high glucose-related tumor microenvironment. PubMed 35485648
- Front Oncol, 2021 (senior author): Wilms' Tumor 1-Associated Protein Contributes to Chemo-Resistance to Cisplatin Through the Wnt/β-Catenin Pathway in Endometrial Cancer. PubMed 33680959
- Transl Cancer Res, 2020 (senior author): Whole-exome sequencing in cervical adenocarcinoma in mainland Chinese patients. PubMed 35117297
- Exp Cell Res, 2020 (senior author): Drp1 mediates high glucose-induced mitochondrial dysfunction and epithelial-mesenchymal transition in endometrial cancer cells. PubMed 32017930
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion